Calliditas Announces NefIgArd Open Label Extension Results
Author: Benzinga Newsdesk | April 24, 2024 03:29am
Calliditas Therapeutics AB (NASDAQ:CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration (UPCR) and estimated glomerular filtration rate (eGFR) at 9 months across all IgAN patients, including those who had previously received Nefecon in the NefIgArd study.
Posted In: CALT